Literature DB >> 9341570

Amyotrophic lateral sclerosis. Insights from genetics.

R H Brown1.   

Abstract

Amyotrophic lateral sclerosis (ALS) is among the most dire neurological diseases. The essential clinical feature of the disorder is relentless, lethal paralysis, usually beginning in midadult years. The disease is caused by a slow, progressive loss of motor neurons in the brain and spinal cord. It usually begins focally and then spreads. In most cases, there is concurrent involvement of corticospinal (upper) and spinal (lower) motor neurons, although in some instances the spinal motor neuron features predominate. Involvement of the spinal motor neurons produces muscle denervation of the affected muscles and fasciculations, followed by muscle atrophy. When corticospinal motor neurons degenerate, the weakness is accompanied by spasticity. The mean age at onset of ALS is 55 years; the mean duration is about 4 years. The incidence of new cases is approximately 1 per 100,000 population. The total number of cases is about 5 per 100,000 population. In the United States, it is estimated that there are 20,000 to 30,000 cases. About 10% of cases are inherited as an autosomal dominant trait; familial and sporadic ALS are clinically indistinguishable.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9341570     DOI: 10.1001/archneur.1997.00550220050013

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  29 in total

Review 1.  Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.

Authors:  Ying Liu; Wenbin Deng
Journal:  Brain Res       Date:  2015-09-28       Impact factor: 3.252

2.  Complexity analysis of stride interval time series by threshold dependent symbolic entropy.

Authors:  Wajid Aziz; Muhammad Arif
Journal:  Eur J Appl Physiol       Date:  2006-07-14       Impact factor: 3.078

3.  Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model.

Authors:  Francesco Paolo Di Giorgio; Monica A Carrasco; Michelle C Siao; Tom Maniatis; Kevin Eggan
Journal:  Nat Neurosci       Date:  2007-04-15       Impact factor: 24.884

Review 4.  Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics.

Authors:  P C Wong; H Cai; D R Borchelt; D L Price
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

5.  Novel role of phosphorylation in Fe-S cluster stability revealed by phosphomimetic mutations at Ser-138 of iron regulatory protein 1.

Authors:  N M Brown; S A Anderson; D W Steffen; T B Carpenter; M C Kennedy; W E Walden; R S Eisenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 6.  Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation.

Authors:  Robert P Picone; Debra A Kendall
Journal:  Mol Endocrinol       Date:  2015-04-13

Review 7.  Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injury.

Authors:  Charles Nicaise; Dinko Mitrecic; Aditi Falnikar; Angelo C Lepore
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

Review 8.  The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Authors:  Emma L Scotter; Mary E Abood; Michelle Glass
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

9.  Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity.

Authors:  Pingwei Zhao; Sheila Ignacio; Eric C Beattie; Mary E Abood
Journal:  Eur J Neurosci       Date:  2008-02       Impact factor: 3.386

10.  Computer-aided analysis of gait rhythm fluctuations in amyotrophic lateral sclerosis.

Authors:  Yunfeng Wu; Sridhar Krishnan
Journal:  Med Biol Eng Comput       Date:  2009-08-26       Impact factor: 2.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.